🟢 Generate Biomedicines is trading 5% up in pre-market

Generate Biomedicines is trading at $14.50, up 5.07% in pre-market on October 2, 2026; no clear catalyst has been identified.

• On October 1, the company announced that the first patient had been dosed in its GB-5267 ovarian cancer trial, but available coverage does not establish that this news explains the move.
• Biotech sector weakness has also been reported, but it does not clearly account for the upward move.